Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition

v3.20.2
Revenue Recognition
6 Months Ended
Jun. 30, 2020
Revenue Recognition [Abstract]  
Revenue Recognition
3.   Revenue Recognition

 

Revenue by Service Line

 

    Three Months Ended June 30,  
    2020     2019  
Products:            
Disposable products:                
Functional neurosurgery   $ 1,049,015     $ 1,690,122  
Biologics and drug delivery     406,955       244,949  
Therapy     21,300       17,830  
Capital equipment     115,800       241,293  
Total product revenue     1,593,070       2,194,194  
Services:                
Capital equipment and other     123,998       243,954  
Biologics and drug delivery     760,714       168,250  
Total service revenue     884,712       412,204  
Total revenue   $ 2,477,782     $ 2,606,398  

 

    Six Months Ended June 30,  
    2020     2019  
Products:                
Disposable products:                
Functional neurosurgery   $ 2,733,424     $ 3,294,767  
Biologics and drug delivery     580,330       529,859  
Therapy     78,800       17,830  
Capital equipment     303,901       515,692  
Total product revenue     3,696,455       4,358,148  
Services:                
Capital equipment and other     280,493       455,156  
Biologics and drug delivery     1,616,428       265,611  
Total service revenue     1,896,121       720,767  
Total revenue   $ 5,593,376     $ 5,078,915  

 

Contract Balances

 

· Contract assets – Substantially all the Company’s contracts with customers are based on customer-issued purchase orders for distinct products or services. Customers are billed upon delivery of such products or services, and the related contract assets comprise the accounts receivable balances included in the accompanying condensed consolidated balance sheets.

 

· Contract liabilities – The Company generally bills and collects capital equipment-related service fees at the inception of the service agreements, which have terms ranging from one to three years. The unearned portion of such service fees are classified as deferred revenue.

 

During the three and six months ended June 30, 2020, the Company recognized capital equipment-related service revenue of approximately $89,000 and $210,000, respectively, which was previously included in deferred revenue in the accompanying condensed consolidated balance sheet at December 31, 2019.

 

In September 2019, the Company entered into a Development Services Agreement with a customer under which the Company was entitled to bill the customer for an upfront payment of $127,600, of which $83,000 and $102,000 are included in deferred revenue in the accompanying June 30, 2020 and December 31, 2019 condensed consolidated balance sheets, respectively.

 

Also, in September 2019, the Company entered into a Letter of Intent, followed by a related Statement of Work (together with the Letter of Intent, the “Project Documents”) in November 2019, with a customer which is a stockholder and whose then Chief Operating Officer was a member of the Company’s Board of Directors (and was subsequently replaced with the customer’s Chief Development Officer), to commence a product development project. Under the terms of the Project Documents, the Company was entitled to bill the customer for: (a) an upfront, nonrefundable payment of $500,000; and (b) quarterly service fees of $500,000 commencing in the fourth quarter of 2019. In February 2020, the Company entered into a Supply Agreement and a Statement of Work (the “European SOW”) with a European affiliate of the customer. Under the terms of the European SOW, the Company was entitled to bill the customer on a quarterly basis, commencing in the first quarter of 2020, for service fees of $250,000. During the six months ended June 30, 2020, the clinical trials contemplated by the Project Documents and the European SOW were delayed as a result of the COVID-19 pandemic. As a result, the Company agreed to reduce such quarterly service fees by an aggregate of $100,000 and $200,000 during the three and six months ended June 30, 2020, respectively. The Company recognizes as revenue each of the upfront payments described in this paragraph in proportional relationship to the transaction prices of the performance obligations contained in the related agreements, and recognizes as revenue the quarterly service fees described in this paragraph as stand-by services beginning in the quarter such services commenced. Based on the foregoing, approximately $429,000 and $625,000 of the aggregate amount of all the payments described in this paragraph were included in deferred revenue in the accompanying condensed consolidated balance sheets at June 30, 2020 and December 31, 2019, respectively.

 

The Company offers an upgraded version of its software at no additional charge to customers purchasing a three-year systems service agreement. The transaction prices of the software and the service agreement are determined through an allocation of the service agreement price based on the standalone prices of the software and the service agreements. The transaction price of the software is recognized as revenue upon its installation and comprised approximately $143,000 and $172,000 of unbilled accounts receivable at June 30, 2020 and December 31, 2019, respectively.

 

Remaining Performance Obligations

 

The Company’s contracts with customers, other than capital equipment-related service agreements discussed below, are predominantly of terms less than one year. Accordingly, the transaction price of remaining performance obligations related to such contracts at June 30, 2020 are not material.

 

Revenue with respect to remaining performance obligations related to capital equipment-related service agreements with original terms in excess of one year and the upfront payments discussed under the heading “Contract Balances” above amounted to approximately $672,000 at June 30, 2020. The Company expects to recognize this revenue within the next three years.